SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-003462 to Oculis Holding AG (OCS, OCSAW) (CIK 0001953530) (OCS)

Oculis Holding AG (OCS, OCSAW) (CIK 0001953530)
Date: April 1, 2024 · CIK: 0001953530 · Accession: 0000000000-24-003462

AI Filing Summary & Sentiment

File numbers found in text: 333-278409

Date
April 1, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Oculis Holding AG (OCS, OCSAW) (CIK 0001953530)

Letter

United States securities and exchange commission logo April 1, 2024 Riad Sherif Chief Executive Officer Oculis Holding AG Bahnhofstrasse 7 CH-6300 Zug, Switzerland Re:Oculis Holding AG Registration Statement on Form F-3 Filed April 1, 2024 File No. 333-278409 Dear Riad Sherif: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Katie Kazem, Esq.

Show Raw Text
United States securities and exchange commission logo
April 1, 2024
Riad Sherif
Chief Executive Officer
Oculis Holding AG
Bahnhofstrasse 7
CH-6300
Zug, Switzerland
Re:Oculis Holding AG
Registration Statement on Form F-3
Filed April 1, 2024
File No. 333-278409
Dear Riad Sherif:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Katie Kazem, Esq.